Paclitaxel (Taxol) (Synonyms: NSC 125973) |
| Catalog No.GC12511 |
Paclitaxel (Taxol)은 Taxus brevifolia의 껍질과 바닥침에서 나오는 삼환 이둘판화합성물질이다.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 33069-62-4
Sample solution is provided at 25 µL, 10mM.
Paclitaxel (Taxol)은 Taxus brevifolia의 껍질과 바닥침에서 나오는 삼환 이둘판화합성물질이다. Paclitaxel (Taxol)은 미관 단백질을 미관으로 조립하고 미관의 해체를 방지하여 세포 주기 진행을 막고 유사분열을 방지하며 암세포의 성장을 억제한다.[1]
체외 실험에서 Paclitaxel은 ATC 세포의 증식을 뚜렷한 용량 종속적인 방식으로 억제하였으며, IC50 값은 1.99에서 9.97 나노몰 사이 범위를 차지하였다. [6] Paclitaxel을 나노 약물 운반체에 포장함으로써 그의 수용성, 암에 대한 선택적 운송, 조직 독성, 제어된 방출 및 Paclitaxel의 약동학 특성이 향상되어, 인체에 대한 독성을 높이고 그의 활성을 유지하거나 강화하며, 그의 약동학 특성을 개선할 수 있다. [2] 체외 실험에서 짧은 시간 동안 Paclitaxel에 노출되었을 때 IkappaB-alpha의 효소화 및 분해를 유도하여, 인간 유방암 BCap37 세포와 인간 피부암 KB 세포 모두에서 NF-kappaB의 활성화를 유도하였다. [3] 또한 Paclitaxel은 자가 난자 전립선암 세포 유래 EVs에 Paclitaxel을 적재함으로써 그의 세포 독성을 증가시킬 수 있다. [5]
체내 실험은 1 mg/kg 및 20 mg/kg Paclitaxel 치료로 인해 저용량 Paclitaxel 처리한 쥐의 간에서 연한색 반점이 크게 증가했으며, 고용량 Paclitaxel 그룹의 전이가 현저히 감소했다는 것을 보여주었다. [4] 체내에서 렌바티니비 처리(5 mg/kg; 구강 투여) 및 Paclitaxel 처리(5 mg/kg; p.o.)를 받은 C643 세포 유래 외래 이식 종양의 성장 속도는 컨트롤 그룹보다 느렸다. [6]
References:
[1]Zhu L, Chen L. Progress in research on paclitaxel and tumor immunotherapy. Cell Mol Biol Lett. 2019 Jun 13;24:40.
[2]Chen S, et al. Recent Development of Copolymeric Nano-Drug Delivery System for Paclitaxel. Anticancer Agents Med Chem. 2020;20(18):2169-2189.?
[3]Dziadyk JM, et al. Paclitaxel-induced apoptosis may occur without a prior G2/M-phase arrest. Anticancer Res. 2004 Jan-Feb;24(1):27-36.?
[4]Li Q, et al. Low doses of paclitaxel enhance liver metastasis of breast cancer cells in the mouse model. FEBS J. 2016 Aug;283(15):2836-52.
[5]Saari H, et al. Microvesicle- and exosome-mediated drug delivery enhances the cytotoxicity of Paclitaxel in autologous prostate cancer cells. J Control Release. 2015 Dec 28;220(Pt B):727-37.?
[6]Jing C, et al. Lenvatinib enhances the antitumor effects of paclitaxel in anaplastic thyroid cancer. Am J Cancer Res. 2017 Apr 1;7(4):903-912.
| 세포 실험 [1]: | |
세포 라인 | MCF-7와 MDA-MB-231 인간 유방암 세포 라인 |
제조 방법 | 세포는 제조사의 권장 사항에 따라 Lipofectamine을 사용하여 p21 프로모터-루시페라스 보고자 유전자 구조체로 일시적으로 전사되었습니다. 전사 후 세포는 12시간 동안 배양되었고 배양액이 교체되었으며, 20 nM Paclitaxel이 존재하는 상황에서 다양한 기간 동안 배양되었습니다. |
반응 조건 | 20 nM; 12h |
응용 분야 | 처리하지 않은 대조 세포는 48시간 배양 기간 동안 지수 증가를 보였으며, paclitaxel (taxol) 처리로 인해 살아 있는 세포의 수가 크게 감소하였습니다. |
| 동물 실험 [2]: | |
동물 모형 | 특정 병원균 자유로운 누드 쥐 |
제조 방법 | MDA-231 세포(1 × 106)가 피하에 이식되었습니다. 기본 종양 형성(지름 > 5 mm) 후, 쥐는 무작위로 그룹화(각 그룹당 10마리) 되었고 1 mg/kg paclitaxel은 정상 소금물에 희석되어 복강 주사(2일에 한 번)로 투여되었습니다. |
제형 | |
응용 분야 | Paclitaxel (1 mg/kg, i.p.)은 간에서 에스트로겐 대사에 변화를 유도하여 유방암 전이 형성을 촉진합니다. |
참고문헌: [1]. [1]Choi YH, Yoo YH. Taxol-induced growth arrest and apoptosis is associated with the upregulation of the Cdk inhibitor, p21WAF1/CIP1, in human breast cancer cells. Oncol Rep. 2012 Dec;28(6):2163-9. [2]. Li Q, et al. Low doses of paclitaxel enhance liver metastasis of breast cancer cells in the mouse model. FEBS J. 2016 Aug;283(15):2836-52. | |
| Cas No. | 33069-62-4 | SDF | |
| Synonyms | NSC 125973 | ||
| Canonical SMILES | O=C(N[C@H]([C@H](C(O[C@H]1C[C@]2(O)C(C)(C)C([C@@H](OC(C)=O)C([C@@]3(C)[C@]([C@@](CO4)(OC(C)=O)[C@H]4C[C@@H]3O)([H])[C@@H]2OC(C5=CC=CC=C5)=O)=O)=C1C)=O)O)C6=CC=CC=C6)C7=CC=CC=C7 | ||
| Formula | C47H51NO14 | M.Wt | 853.91 |
| Solubility | ≥ 42.6955mg/mL in DMSO, ≥ 31.6 mg/mL in EtOH with ultrasonic | Storage | 4°C, protect from light |
| General tips | Please select the appropriate solvent to prepare the stock solution according to the
solubility of the product in different solvents; once the solution is prepared, please store it in
separate packages to avoid product failure caused by repeated freezing and thawing.Storage method
and period of the stock solution: When stored at -80°C, please use it within 6 months; when stored
at -20°C, please use it within 1 month. To increase solubility, heat the tube to 37°C and then oscillate in an ultrasonic bath for some time. |
||
| Shipping Condition | Evaluation sample solution: shipped with blue ice. All other sizes available: with RT, or with Blue Ice upon request. | ||
| Prepare stock solution | |||
|
1 mg | 5 mg | 10 mg |
| 1 mM | 1.1711 mL | 5.8554 mL | 11.7108 mL |
| 5 mM | 234.2 μL | 1.1711 mL | 2.3422 mL |
| 10 mM | 117.1 μL | 585.5 μL | 1.1711 mL |
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
g
μL
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.
3. All of the above co-solvents are available for purchase on the GlpBio website.
Quality Control & SDS
- View current batch:
- Purity: >99.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
-
Related Biological Data
PTX damages mitochondria and generates ROS. (b) DCFH-DA fluorescent probe was used to detect the ROS content in PC3M cells under PTX treatment. Bar, 50 μm.
1 × 104 PC3M cells were cultured in 35 mm glass-bottom cell culture dishes for 24 h and added medium containing DMSO (3 μL/mL), PTX (2μM,GLPBIO), and/or NAC (5 mM) to treat cells in different groups for another 24h.
Talanta, 2023: 125355. PMID: 37952317 IF: 6.1004 -
Related Biological Data
WP1066 rescues paclitaxel-enhanced STAT3-Stathmin interaction and causes microtubule morphological change in ovarian cancer cells. (G). WP1066 promoted microtubule to be more instable while paclitaxel facilitated microtubule to be more stable in SKOV3 cells.
Paclitaxel-resistant SKOV3/PTX and A2780/PTX cells were established by a stepwise increase in paclitaxel (PTX), and maintained in the culture medium containing 10 ng/ml PTX(GLPBIO), while the parental cell lines were passaged in the absence of PTX.
Biochemical Pharmacology (2024): 116040. PMID: 38311257 IF: 5.8000 -
Related Biological Data
Downregulation of TRAF3 reduces the sensitivity of LUAD cells to paclitaxel (A) CCK-8 assay was applied to evaluate the effect of different concentrations of paclitaxel on the cell viability of A549 cells after transfection.
After incubating for 24 h, cells were adhered and grown in the wells. Then, 10 ul of paclitaxel (GlpBio, USA) was added at different concentrations and incubated for 48 h.
BMC cancer, 2023, 23(1): 1-9. PMID: 37798663 IF: 3.8001 -
Related Biological Data
Inhibition of MUC1 promoted apoptosis of A549/PR cells in treatment of paclitaxel. (B) Quantified results of A were presented.
Paclitaxel‑resistant NSCLC cell lines A549/PR were treated with 0.5 μM of paclitaxel (Glpbio) in the culture for 3 months.
Mol Med Rep 22.4 (2020): 2966-2972. PMID: 32945387 IF: 2.9500
Average Rating: 5 (Based on Reviews and 30 reference(s) in Google Scholar.)
GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *